Yeda Research and Develpment & Co. Ltd

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Moran Rawet Slobodkin

Zelig Eshhar

Tova Waks

Anat Globerson Levin

Naamit Deshet-unger

Ben Zion Katz

Ido Laskov

The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.

T-cells comprising two different chimeric antigen receptors and uses thereof

The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

Growing community of inventors

Tel Aviv, Israel

Moran Rawet Slobodkin